As of Dec 02
| +0.23 / +6.44%|
The 1 analysts offering 12-month price forecasts for MabVax Therapeutics Holdings Inc have a median target of 18.00, with a high estimate of 18.00 and a low estimate of 18.00. The median estimate represents a +373.68% increase from the last price of 3.80.
The current consensus among 1 polled investment analysts is to Buy stock in MabVax Therapeutics Holdings Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.